Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Liljeström P[au]:

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Zhu J et al. Nat Commun. (2017)

Self-replicating alphavirus RNA vaccines. Ljungberg K et al. Expert Rev Vaccines. (2015)

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. Roques P et al. JCI Insight. (2017)

Search results

Items: 1 to 50 of 139

1.

Seroreactivity to Chikungunya and West Nile Viruses in Rwandan Blood Donors.

Seruyange E, Ljungberg K, Muvunyi CM, Gahutu JB, Katare S, Nyamusore J, Gwon YD, Evander M, Norder H, Liljeström P, Bergström T.

Vector Borne Zoonotic Dis. 2019 Oct;19(10):731-740. doi: 10.1089/vbz.2018.2393. Epub 2019 Jun 27.

PMID:
31246538
2.

Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.

Marín MQ, Pérez P, Ljungberg K, Sorzano CÓS, Gómez CE, Liljeström P, Esteban M, García-Arriaza J.

J Virol. 2019 Mar 21;93(7). pii: e00055-19. doi: 10.1128/JVI.00055-19. Print 2019 Apr 1.

3.

Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens.

van de Wall S, Ljungberg K, Ip PP, Boerma A, Knudsen ML, Nijman HW, Liljeström P, Daemen T.

Oncoimmunology. 2018 Jul 26;7(10):e1487913. doi: 10.1080/2162402X.2018.1487913. eCollection 2018.

4.

DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost.

Öhlund P, García-Arriaza J, Zusinaite E, Szurgot I, Männik A, Kraus A, Ustav M, Merits A, Esteban M, Liljeström P, Ljungberg K.

Sci Rep. 2018 Aug 20;8(1):12459. doi: 10.1038/s41598-018-31003-6.

5.

Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

Lázaro-Frías A, Gómez-Medina S, Sánchez-Sampedro L, Ljungberg K, Ustav M, Liljeström P, Muñoz-Fontela C, Esteban M, García-Arriaza J.

J Virol. 2018 May 14;92(11). pii: e00363-18. doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.

6.

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Zhu J, Powis de Tenbossche CG, Cané S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van den Eynde BJ.

Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.

7.

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.

Roques P, Ljungberg K, Kümmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, Hallengärd D, García-Arriaza J, Meinke A, Esteban M, Merits A, Le Grand R, Liljeström P.

JCI Insight. 2017 Mar 23;2(6):e83527. doi: 10.1172/jci.insight.83527.

8.

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.

Rollier CS, Verschoor EJ, Verstrepen BE, Drexhage JA, Paranhos-Baccala G, Liljeström P, Sutter G, Arribillaga L, Lasarte JJ, Bartosch B, Cosset FL, Inchauspe G, Heeney JL.

Gene Ther. 2016 Oct;23(10):753-759. doi: 10.1038/gt.2016.55. Epub 2016 Jul 14.

PMID:
27416077
9.

H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep-wake regulatory neurons in mice.

Tesoriero C, Codita A, Zhang MD, Cherninsky A, Karlsson H, Grassi-Zucconi G, Bertini G, Harkany T, Ljungberg K, Liljeström P, Hökfelt TG, Bentivoglio M, Kristensson K.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E368-77. doi: 10.1073/pnas.1521463112. Epub 2015 Dec 14.

10.

A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.

Feltelius N, Persson I, Ahlqvist-Rastad J, Andersson M, Arnheim-Dahlström L, Bergman P, Granath F, Adori C, Hökfelt T, Kühlmann-Berenzon S, Liljeström P, Maeurer M, Olsson T, Örtqvist Å, Partinen M, Salmonson T, Zethelius B.

J Intern Med. 2015 Oct;278(4):335-53. doi: 10.1111/joim.12391. Epub 2015 Jun 30. Review.

11.

Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.

Borthwick NJ, Rosario M, Schiffner T, Bowles E, Ahmed T, Liljeström P, Stewart-Jones GE, Drijfhout JW, Melief CJ, Hanke T.

Immun Inflamm Dis. 2015 Jun;3(2):82-93. doi: 10.1002/iid3.52. Epub 2015 Mar 11.

12.

Therapeutics and vaccines against chikungunya virus.

Ahola T, Couderc T, Ng LF, Hallengärd D, Powers A, Lecuit M, Esteban M, Merits A, Roques P, Liljeström P.

Vector Borne Zoonotic Dis. 2015 Apr;15(4):250-7. doi: 10.1089/vbz.2014.1681. Review. Erratum in: Vector Borne Zoonotic Dis. 2015 Nov;15(11):712. Courderc, Therese [Corrected to Couderc, Therese].

PMID:
25897811
13.

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.

Knudsen ML, Ljungberg K, Tatoud R, Weber J, Esteban M, Liljeström P.

PLoS One. 2015 Feb 2;10(2):e0117042. doi: 10.1371/journal.pone.0117042. eCollection 2015.

14.

Modification of a salmonid alphavirus replicon vector for enhanced expression of heterologous antigens.

Guo TC, Johansson DX, Liljeström P, Evensen Ø, Haugland Ø.

J Gen Virol. 2015 Mar;96(Pt 3):565-70. doi: 10.1099/vir.0.067348-0. Epub 2014 Nov 13.

PMID:
25395591
15.

Self-replicating alphavirus RNA vaccines.

Ljungberg K, Liljeström P.

Expert Rev Vaccines. 2015 Feb;14(2):177-94. doi: 10.1586/14760584.2015.965690. Epub 2014 Oct 1. Review.

PMID:
25269775
16.

Prime-boost immunization strategies against Chikungunya virus.

Hallengärd D, Lum FM, Kümmerer BM, Lulla A, Lulla V, García-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LF, Esteban M, Liljeström P.

J Virol. 2014 Nov;88(22):13333-43. doi: 10.1128/JVI.01926-14. Epub 2014 Sep 10.

17.

Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations.

Knudsen ML, Ljungberg K, Kakoulidou M, Kostic L, Hallengärd D, García-Arriaza J, Merits A, Esteban M, Liljeström P.

J Virol. 2014 Nov;88(21):12438-51. doi: 10.1128/JVI.02223-14. Epub 2014 Aug 13.

18.

A 6K-deletion variant of salmonid alphavirus is non-viable but can be rescued through RNA recombination.

Guo TC, Johansson DX, Haugland Ø, Liljeström P, Evensen Ø.

PLoS One. 2014 Jul 10;9(7):e100184. doi: 10.1371/journal.pone.0100184. eCollection 2014.

19.

Intradermal electroporation of RNA.

Knudsen ML, Ljungberg K, Liljeström P, Johansson DX.

Methods Mol Biol. 2014;1121:147-54. doi: 10.1007/978-1-4614-9632-8_13.

PMID:
24510820
20.

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M.

J Virol. 2014 Mar;88(6):3527-47. doi: 10.1128/JVI.03418-13. Epub 2014 Jan 8.

21.

Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.

Hallengärd D, Kakoulidou M, Lulla A, Kümmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljeström P.

J Virol. 2014 Mar;88(5):2858-66. doi: 10.1128/JVI.03453-13. Epub 2013 Dec 26.

22.

Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout.

Gläsker S, Lulla A, Lulla V, Couderc T, Drexler JF, Liljeström P, Lecuit M, Drosten C, Merits A, Kümmerer BM.

Virol J. 2013 Jul 15;10:235. doi: 10.1186/1743-422X-10-235.

23.

The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon.

Knudsen ML, Johansson DX, Kostic L, Nordström EK, Tegerstedt K, Pasetto A, Applequist SE, Ljungberg K, Sirard JC, Liljeström P.

PLoS One. 2013 Jun 13;8(6):e65964. doi: 10.1371/journal.pone.0065964. Print 2013.

24.

Host gene expression signatures discriminate between ferrets infected with genetically similar H1N1 strains.

Ljungberg K, McBrayer A, Camp JV, Chu YK, Tapp R, Noah DL, Grimes S, Proctor ML, Liljeström P, Jonsson CB, Bruder CE.

PLoS One. 2012;7(7):e40743. doi: 10.1371/journal.pone.0040743. Epub 2012 Jul 13.

25.

De-novo transcriptome sequencing of a normalized cDNA pool from influenza infected ferrets.

Camp JV, Svensson TL, McBrayer A, Jonsson CB, Liljeström P, Bruder CE.

PLoS One. 2012;7(5):e37104. doi: 10.1371/journal.pone.0037104. Epub 2012 May 11.

26.

Differential impact of interferon regulatory factor 7 in initiation of the type I interferon response in the lymphocytic choriomeningitis virus-infected central nervous system versus the periphery.

Christensen JE, Fenger C, Issazadeh-Navikas S, Krug A, Liljestrøm P, Goriely S, Paludan SR, Finsen B, Christensen JP, Thomsen AR.

J Virol. 2012 Jul;86(13):7384-92. doi: 10.1128/JVI.07090-11. Epub 2012 Apr 18.

27.

Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.

Knudsen ML, Mbewe-Mvula A, Rosario M, Johansson DX, Kakoulidou M, Bridgeman A, Reyes-Sandoval A, Nicosia A, Ljungberg K, Hanke T, Liljeström P.

J Virol. 2012 Apr;86(8):4082-90. doi: 10.1128/JVI.06535-11. Epub 2012 Feb 8.

28.

Intradermal electroporation of naked replicon RNA elicits strong immune responses.

Johansson DX, Ljungberg K, Kakoulidou M, Liljeström P.

PLoS One. 2012;7(1):e29732. doi: 10.1371/journal.pone.0029732. Epub 2012 Jan 4.

29.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M.

Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9.

PMID:
21907749
30.

Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges.

Im EJ, Hong JP, Roshorm Y, Bridgeman A, Létourneau S, Liljeström P, Potash MJ, Volsky DJ, McMichael AJ, Hanke T.

PLoS Pathog. 2011 May;7(5):e1002041. doi: 10.1371/journal.ppat.1002041. Epub 2011 May 19.

31.

Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines.

Näslund TI, Kostic L, Nordström EK, Chen M, Liljeström P.

Virol J. 2011 Jan 24;8:36. doi: 10.1186/1743-422X-8-36.

32.

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.

Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, Ammendola V, Ljungberg K, Borthwick N, Im EJ, McMichael AJ, Drijfhout JW, Greenaway HY, Venturi V, Douek DC, Colloca S, Liljeström P, Nicosia A, Price DA, Melief CJ, Hanke T.

Eur J Immunol. 2010 Jul;40(7):1973-84. doi: 10.1002/eji.201040344.

33.

Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model.

Wild J, Bieler K, Köstler J, Frachette MJ, Jeffs S, Vieira S, Esteban M, Liljeström P, Pantaleo G, Wolf H, Wagner R.

Viral Immunol. 2009 Oct;22(5):309-19. doi: 10.1089/vim.2009.0038.

PMID:
19811088
34.

Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.

Mooij P, Balla-Jhagjhoorsingh SS, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Heidari S, Wolf H, Frachette MJ, Bieler K, Sheppard N, Harari A, Bart PA, Liljeström P, Wagner R, Pantaleo G, Heeney JL.

J Virol. 2009 Jun;83(11):5881-9. doi: 10.1128/JVI.02345-08. Epub 2009 Mar 25.

35.

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, Sheppard NC, Bangala Y, Frachette MJ, Wagner R, Liljeström P, Kraehenbuhl JP, Girard M, Goudsmit J, Esteban M, Heeney J, Sattentau Q, McCormack S, Babiker A, Pantaleo G, Weber J; EuroVacc Consortium.

Vaccine. 2008 Jun 13;26(25):3153-61. doi: 10.1016/j.vaccine.2008.03.083. Epub 2008 May 27.

PMID:
18502002
36.

Expression of proteins using Semliki Forest virus vectors.

Liljeström P, Garoff H.

Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.20. doi: 10.1002/0471142727.mb1620s29.

PMID:
18265128
37.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G.

J Exp Med. 2008 Jan 21;205(1):63-77. doi: 10.1084/jem.20071331. Epub 2008 Jan 14.

38.

Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector.

Forsell MN, McInerney GM, Dosenovic P, Hidmark AS, Eriksson C, Liljeström P, Grundner C, Karlsson Hedestam GB.

J Gen Virol. 2007 Oct;88(Pt 10):2774-9.

PMID:
17872531
39.

Semliki Forest virus nonstructural protein 2 is involved in suppression of the type I interferon response.

Breakwell L, Dosenovic P, Karlsson Hedestam GB, D'Amato M, Liljeström P, Fazakerley J, McInerney GM.

J Virol. 2007 Aug;81(16):8677-84. Epub 2007 Jun 6.

40.

Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.

Näslund TI, Uyttenhove C, Nordström EK, Colau D, Warnier G, Jondal M, Van den Eynde BJ, Liljeström P.

J Immunol. 2007 Jun 1;178(11):6761-9.

41.

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljeström P, Wagner R, Esteban M.

Vaccine. 2007 Mar 1;25(11):1969-92. Epub 2006 Dec 6.

PMID:
17224219
42.

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M.

Vaccine. 2007 Apr 12;25(15):2863-85. Epub 2006 Oct 16.

PMID:
17113200
43.

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates.

Pichlmair A, Schulz O, Tan CP, Näslund TI, Liljeström P, Weber F, Reis e Sousa C.

Science. 2006 Nov 10;314(5801):997-1001. Epub 2006 Oct 12.

44.

Viral vectors for malaria vaccine development.

Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F.

Vaccine. 2007 Mar 30;25(14):2567-74. Epub 2006 Aug 1. Review.

PMID:
16914237
45.

Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling.

Hidmark AS, Nordström EK, Dosenovic P, Forsell MN, Liljeström P, Karlsson Hedestam GB.

J Virol. 2006 Jul;80(14):7100-10.

46.

Relation between viral fitness and immune escape within the hepatitis C virus protease.

Söderholm J, Ahlén G, Kaul A, Frelin L, Alheim M, Barnfield C, Liljeström P, Weiland O, Milich DR, Bartenschlager R, Sällberg M.

Gut. 2006 Feb;55(2):266-74. Epub 2005 Aug 16.

47.

Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Forsell MN, Li Y, Sundbäck M, Svehla K, Liljeström P, Mascola JR, Wyatt R, Karlsson Hedestam GB.

J Virol. 2005 Sep;79(17):10902-14.

48.

Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.

Sundbäck M, Douagi I, Dayaraj C, Forsell MN, Nordström EK, McInerney GM, Spångberg K, Tjäder L, Bonin E, Sundström M, Liljeström P, Karlsson Hedestam GB.

Virology. 2005 Oct 25;341(2):190-202. Epub 2005 Aug 10.

49.

Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.

Rollier C, Verschoor EJ, Paranhos-Baccala G, Drexhage JA, Verstrepen BE, Berland JL, Himoudi N, Barnfield C, Liljestrom P, Lasarte JJ, Ruiz J, Inchauspe G, Heeney JL.

J Infect Dis. 2005 Sep 1;192(5):920-9. Epub 2005 Aug 1.

PMID:
16088843
50.

Early alpha/beta interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88.

Hidmark AS, McInerney GM, Nordström EK, Douagi I, Werner KM, Liljeström P, Karlsson Hedestam GB.

J Virol. 2005 Aug;79(16):10376-85.

Supplemental Content

Loading ...
Support Center